Role Summary
Lexeo’s Commercial team is building the strategy, insights, brand and infrastructure required to bring LX2006 to patients – marking Lexeo’s transition from a clinical-stage to a commercial company.
We are seeking an Associate Director, Marketing to play a central role in preparing for the launch of LX2006, Lexeo’s first commercial product, anticipated in the US in 2028 and globally thereafter. Reporting to the Senior Director, Marketing, this individual will serve as the LX2006 brand lead, owning critical launch workstreams end to end – from customer insights and competitive intelligence to market development, campaigns, customer targeting and launch readiness – and working closely with cross-functional partners in Market Access/HEOR, Medical Affairs, Patient Affairs, Clinical Development, Regulatory, Legal, CMC, and Business Development (ad hoc) as part of Lexeo’s Launch Readiness Team.
The role will also support early commercial planning for LX2020, Lexeo’s gene therapy candidate for PKP2-associated arrhythmogenic cardiomyopathy.
This is a highly visible, hands-on opportunity to build a launch from the ground up and help shape the commercial foundation of a growing clinical stage company.
We welcome applications from candidates located across the Northeast and Mid-Atlantic.
Primary Responsibilities
LX2006 launch strategy and brand planning: Partner with the Senior Director, Marketing to enhance and execute the LX2006 US launch strategy and brand plan, including strategic imperatives, positioning, target patient definition and the pre-launch market development plan. Translate strategy into an integrated launch roadmap and prepare materials for Launch Readiness Reviews, senior leadership and Board discussions as well as investor calls. Define launch KPIs and the analytics and CRM capabilities needed to track launch performance
Launch readiness leadership: Serve as a core member of the cross-functional US and ex-US Launch Readiness Teams. Drive launch timelines, deliverables, interdependencies, risks and decisions across Commercial, Medical Affairs, Patient Affairs, Market Access/HEOR, Regulatory, Clinical, Legal and CMC
Customer insights and market research: Lead the HCP, patient/caregiver, and payer research program for LX2006 (e.g., awareness, trial and usage tracking, demand studies, message and concept testing, advisory boards). Distill findings into clear recommendations that shape positioning, patient segmentation, evidence generation and lifecycle decisions
Competitive intelligence: Own the Friedreich ataxia (FA) competitive intelligence program, including key intelligence questions, monitoring of competitor clinical, regulatory and commercial activity, scenario planning and war gaming, and regular updates to leadership and cross-functional partners
Brand development and campaigns: Lead global brand development for LX2006, including brand naming and trademark activities, brand identity and brand book. Develop and deploy unbranded disease-awareness and branded HCP and patient campaigns across channels, managing creative and media agencies and the medical/legal/regulatory (MLR) review process
Customer targeting and treatment center readiness: Build and refine the prescriber, account and treatment center universe across neurology and cardiology using claims and other third-party data. Define targeting and segmentation, and partner with Medical and Market Access on treatment center mapping, readiness assessments and referral pathways
HCP and KOL engagement: Develop and execute the commercial HCP and KOL engagement plan (e.g., KOL steering committee, peer-to-peer programs, advisory boards, medical congress presence) in compliant partnership with Medical Affairs
Global launch planning: Support ex-US launch sequencing and go-to-market planning, ensuring global brand strategy, insights and materials can be adapted for priority markets as LX2006 expands beyond the US
Field launch readiness: Develop core launch materials (e.g., sales aids, leave-behinds, websites, congress assets) and contribute to field training, launch meeting and plan-of-action planning ahead of field deployment
LX2020 early commercial planning: Support early commercial planning for LX2020 in PKP2-associated arrhythmogenic cardiomyopathy, including target product profile development, HCP and payer research, patient segmentation, market sizing and commercial input to pivotal trial design, leveraging synergies with LX2006
Budget and vendor management: Manage marketing budgets, statements of work and vendor relationships across market research, data, creative and strategy partners; track spend against plan and contribute to annual budget planning
Team building: Help scale the team as we get closer to launch and contribute to a collaborative cross-functional commercial mindset culture
Required Skills and Qualifications
MBA or other advanced degree required
Minimum of 7 years of experience in the biopharmaceutical industry, including direct marketing experience on a launch brand and/or in rare disease. Gene therapy marketing experience is a plus
Demonstrated experience developing brand strategy, positioning and HCP and/or patient campaigns, including agency management and MLR review
Hands-on experience designing and managing primary market research and translating insights into strategy
Strong analytical skills, with comfort working with claims and other secondary data, forecasts and market sizing
Exceptional project management skills and a proven ability to lead cross-functional teams without direct authority while managing multiple workstreams
Excellent written and verbal communication skills, including the ability to synthesize complex information into concise, executive-ready narratives for senior leadership and the Board
Working knowledge of US compliance requirements governing pre-approval and promotional activities
Self-starter with a builder mindset who thrives in a lean, fast-paced, pre-commercial environment
Ability to travel as needed (e.g., medical congresses, advisory boards, vendor and treatment center meetings)
Preferred Skills and Qualifications
Gene therapy or cell and gene therapy launch experience (significant plus)
Prior management or strategy consulting experience in life sciences
Experience in cardiology and/or neurology marketing
Exposure to market access, pricing and reimbursement for high-cost, one-time therapies
Global or ex-US launch experience, including familiarity with HTA requirements
About LEXEO
Lexeo Therapeutics is a New York City-based, clinical stage company dedicated to reshaping the path of genetic disease. By advancing pioneering science, Lexeo seeks to set a new standard in the treatment of cardiovascular and neurological genetic diseases, charting the path to patient outcomes once thought out of reach. The Company is advancing a portfolio of therapeutic candidates designed to address the underlying genetic causes of disease, including LX2006 for Friedreich ataxia (FA), LX2020 for plakophilin-2 (PKP2) arrhythmogenic cardiomyopathy, and others in devastating diseases with high unmet need.
Our work culture is a hybrid model with 2 days in the New York City office and 3 days working from home.
LEXEO Therapeutics is an EEO employer committed to an exciting, diverse, and enriching work environment.